1. Australia's TGA makes ADR reporting easier

   News item 03 November 2018 Pages: 1 - 1

2. Interpol: 500 tonnes of illicit pharmaceuticals seized globally

   News item 03 November 2018 Pages: 2 - 2

3. New Dutch restrictions on supplements containing vitamin B6

   News item 03 November 2018 Pages: 3 - 3

4. Non-melanoma skin cancers with HCTZ-containing medicines

   Correspondence 03 November 2018 Pages: 4 - 4

5. Risk of fatal toxicity with transdermal fentanyl patches

   News item 03 November 2018 Pages: 5 - 5

6. Drug safety professional questionnaire: artificial intelligence

   Clinical study 03 November 2018 Pages: 6 - 6

7. Adverse drug reactions with follitropin-α/lutropin-α

   Clinical study 03 November 2018 Pages: 7 - 7

8. Obinutuzumab, rituximab: risk of hepatitis B reactivation

   Clinical study 03 November 2018 Pages: 8 - 8

9. Pharmacovigilance: role of patient organisations

   Clinical study 03 November 2018 Pages: 9 - 9

10. Sympathomimetic stimulants in dietary supplements

    Clinical study 03 November 2018 Pages: 10 - 10

11. Use of ACE inhibitors increases risk of lung cancer

    Clinical study 03 November 2018 Pages: 11 - 11

12. 17dd yellow fever vaccine

    Case report 03 November 2018 Pages: 12 - 12

13. Acenocoumarol

    Case report 03 November 2018 Pages: 13 - 13

14. Acenocoumarol/linezolid interaction

    Case report 03 November 2018 Pages: 14 - 14

15. Acetazolamide/antiepileptic-drugs

    Case report 03 November 2018 Pages: 15 - 15

16. Acitretin/alitretinoin

    Case report 03 November 2018 Pages: 16 - 16

17. Adalimumab

    Case report 03 November 2018 Pages: 17 - 17

18. Adalimumab

    Case report 03 November 2018 Pages: 18 - 18

19. Adalimumab, etanercept and golimumab

    Case report 03 November 2018 Pages: 19 - 19

20. Afatinib/bevacizumab

    Case report 03 November 2018 Pages: 20 - 20

21. Afatinib/erlotinib

    Case report 03 November 2018 Pages: 21 - 21

22. Aldesleukin

    Case report 03 November 2018 Pages: 22 - 22

23. Alemtuzumab/fingolimod/methylprednisolone

    Case report 03 November 2018 Pages: 23 - 23

24. Alemtuzumab/vedolizumab

    Case report 03 November 2018 Pages: 24 - 24

25. Allopurinol

    Case report 03 November 2018 Pages: 25 - 25

26. Alprazolam/antipsychotics/biperiden

    Case report 03 November 2018 Pages: 26 - 26

27. Ambrisentan

    Case report 03 November 2018 Pages: 27 - 27

28. Amikacin/cotrimoxazole/rifampicin

    Case report 03 November 2018 Pages: 28 - 28

29. Amiodarone

    Case report 03 November 2018 Pages: 29 - 29

30. Amiodarone

    Case report 03 November 2018 Pages: 30 - 30

31. Amlodipine

    Case report 03 November 2018 Pages: 31 - 31

32. Amoxicillin/clavulanic-acid/zopiclone

    Case report 03 November 2018 Pages: 32 - 32

33. Amphotericin B liposomal

    Case report 03 November 2018 Pages: 33 - 33

34. Amphotericin-B

    Case report 03 November 2018 Pages: 34 - 34

35. Analgesics/morphine/oxazepam

    Case report 03 November 2018 Pages: 35 - 35

36. Angiotensin-converting enzyme (ACE) inhibitors

    Case report 03 November 2018 Pages: 36 - 36

37. Antidepressants

    Case report 03 November 2018 Pages: 37 - 37

38. Antidepressants

    Case report 03 November 2018 Pages: 38 - 38

39. Antiepileptics

    Case report 03 November 2018 Pages: 39 - 39

40. Antineoplastic agents

    Case report 03 November 2018 Pages: 40 - 40

41. Antineoplastics

    Case report 03 November 2018 Pages: 41 - 41

42. Antineoplastics

    Case report 03 November 2018 Pages: 42 - 42

43. Antineoplastics

    Case report 03 November 2018 Pages: 43 - 43

44. Antineoplastics

    Case report 03 November 2018 Pages: 44 - 44

45. Antineoplastics

    Case report 03 November 2018 Pages: 45 - 45

46. Antineoplastics

    Case report 03 November 2018 Pages: 46 - 46

47. Antineoplastics

    Case report 03 November 2018 Pages: 47 - 47

48. Antineoplastics

    Case report 03 November 2018 Pages: 48 - 48

49. Antineoplastics

    Case report 03 November 2018 Pages: 49 - 50

50. Antineoplastics

    Case report 03 November 2018 Pages: 50 - 50